Willingness to use and preferences for long‐acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross‐sectional study

• Published in: Journal of the International AIDS Society Vol. 26; no. 3; pp. e26077 - n/a
• Main Authors: Schoenberg, Paige, Edwards, O. Winslow, Merrill, Leland, Martinez, Cristian Acero, Stephenson, Rob, Sullivan, Patrick S., Jones, Jeb
• Format: Journal Article
• Language: English
• Published: Switzerland John Wiley & Sons, Inc 01.03.2023; John Wiley and Sons Inc; Wiley
• Subjects: Acquired immune deficiency syndrome; AIDS; Anti-HIV Agents; Antiretroviral drugs; Confidence intervals; Cross-Sectional Studies; Demographics; Disease prevention; Drug dosages; Epidemics; Ethnicity; Family income; FDA approval; Gender identity; Health insurance; Hispanic Americans; HIV; HIV Infections - epidemiology; HIV Infections - prevention & control; Homosexuality, Male; Human immunodeficiency virus; Human subjects; Humans; injectable; Male; men who have sex with men; Minority & ethnic groups; Non-binary gender; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Preferences; Prophylaxis; Rural areas; Sexual and Gender Minorities; sexual and gender minority populations; Sexual Behavior; Sexually transmitted diseases; Short Report; Social networks; STD; Stigma; transgender people; Transgender persons; United States; United States; United States > US; Southern states; transgender people; injectable; pre-exposure prophylaxis; sexual and gender minority populations; HIV; men who have sex with men

Introduction Long‐acting injectable (LAI) pre‐exposure prophylaxis (PrEP) for HIV prevention was approved by the U.S. Food and Drug Administration in 2021. LAI PrEP is more effective than oral PrEP. However, it is not clear whether the groups most at risk of HIV in the United States will use LAI PrE...